Co-administration of Ciprofloxacin and Fezolinetant
Ciprofloxacin can be co-administered with fezolinetant, but expect a moderate increase in fezolinetant exposure (approximately 1.4-1.5 fold increase in Cmax and 2.0-2.3 fold increase in AUC) due to CYP1A2 inhibition. This interaction is clinically manageable and does not require routine dose adjustment of fezolinetant, though monitoring for fezolinetant-related adverse effects is prudent.
Mechanism of Interaction
Fezolinetant is primarily metabolized by CYP1A2 and is classified as a sensitive CYP1A2 substrate 1. Ciprofloxacin acts as a moderate CYP1A2 inhibitor 2, which reduces the clearance of fezolinetant and increases its systemic exposure.
PBPK modeling specifically predicts that ciprofloxacin co-administration increases fezolinetant Cmax by 1.39-1.49 fold and AUC by 1.99-2.33 fold, depending on dosing regimen and meal status 1. This magnitude of increase is less than what occurs with strong CYP1A2 inhibitors like fluvoxamine, but more substantial than weak inhibitors like cimetidine.
Clinical Management Algorithm
Before Starting Co-administration:
- Assess baseline fezolinetant tolerability: If the patient is already experiencing headache (the most common adverse effect at 5-10%) 3, consider whether additional exposure increase is acceptable
- Review ciprofloxacin indication and duration: Short courses (3-14 days) for acute infections pose less cumulative risk than prolonged therapy
During Co-administration:
Monitor for fezolinetant adverse effects, particularly:
Liver function monitoring: Fezolinetant requires baseline and periodic liver function testing 6. If ciprofloxacin is started during fezolinetant therapy, consider checking LFTs given the increased drug exposure
No routine dose adjustment of fezolinetant is required based on the moderate magnitude of interaction 1
Ciprofloxacin-Specific Considerations:
The British Thoracic Society guidelines detail extensive ciprofloxacin monitoring requirements 7:
- ECG monitoring: Baseline, at 2 weeks, and after adding any QT-prolonging medication (ciprofloxacin can rarely cause QTc prolongation)
- Timing with other medications: Ciprofloxacin absorption is reduced by multivalent cations (take 1-2 hours before or 4 hours after antacids, calcium, iron, magnesium)
- Hydration: Ensure adequate hydration to prevent crystalluria
Important Caveats
The interaction is bidirectional but asymmetric: While ciprofloxacin significantly affects fezolinetant levels, fezolinetant does not appear to meaningfully alter ciprofloxacin pharmacokinetics based on its metabolic profile.
Duration matters: The CYP1A2 inhibition by ciprofloxacin is reversible and concentration-dependent. Effects begin within hours of starting ciprofloxacin and resolve within 2-3 days after discontinuation. For short antibiotic courses (3-7 days for UTI, 3 days for chancroid 8), the interaction window is limited.
Patient-specific factors that amplify risk:
- Elderly patients (>65 years): Both drugs show altered pharmacokinetics in this population 2, 6
- Renal impairment: Ciprofloxacin clearance is reduced, potentially prolonging the interaction 2
- Hepatic impairment: May reduce fezolinetant clearance independently
Contraindications to Consider
While the ciprofloxacin-fezolinetant combination itself is not contraindicated, be aware that ciprofloxacin is absolutely contraindicated with tizanidine (7-10 fold increase in tizanidine exposure causing severe hypotension and sedation) 2.
Alternative Antibiotics
If the drug interaction is concerning and alternative antibiotics are appropriate for the infection:
- Azithromycin: Does not inhibit CYP1A2 (though it does inhibit CYP3A4)
- Amoxicillin/clavulanate: No CYP1A2 interaction
- Cephalosporins (cephalexin, cefuroxime): No CYP1A2 interaction
However, antibiotic selection should be primarily driven by infection type, local resistance patterns, and patient factors—not solely by drug interactions 9, 10.
Bottom Line
The ciprofloxacin-fezolinetant interaction is predictable, moderate in magnitude, and clinically manageable without dose adjustment. The 2-fold increase in fezolinetant AUC is within the range studied in clinical trials and does not produce new safety signals 1. Simple monitoring for increased adverse effects during the typically short duration of ciprofloxacin therapy is sufficient. This interaction should not prevent appropriate antibiotic treatment when ciprofloxacin is indicated.